CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 67,257	$ 97,862	$ 265,536	$ 284,186
Expenses:
Selling, general and administrative	27,810	2,860	46,084	13,074
Research and development	11,725	449	31,447	536
Amortization of intangible assets	1,511	0	1,511	0
Gain on sale of Theravance Respiratory Company, LLC ("TRC")	(266,696)	0	(266,696)	0
Loss on extinguishment of debt	0	0	20,662	0
Changes in fair values of equity and long-term investments, net	(130)	(33,613)	67,881	(133,973)
Interest and dividend income	(2,135)	(453)	(3,181)	(503)
Interest expense	5,096	4,790	11,761	14,229
Other expense (income), net	(28)	652	750	2,036
Total expenses	(219,167)	(25,315)	(86,101)	(104,601)
Income before income taxes	286,424	123,177	351,637	388,787
Income tax expense net	57,077	20,531	63,061	65,600
Net income (loss)	229,347	102,646	288,576	323,187
Net income (loss) attributable to noncontrolling interests	(36,176)	30,208	6,341	67,678
Net income attributable to Innoviva stockholders	$ 265,523	$ 72,438	$ 282,235	$ 255,509
Basic net income per share attributable to Innoviva stockholders	$ 3.81	$ 1.04	$ 4.05	$ 2.96
Diluted net income per share attributable to Innoviva stockholders	$ 2.80	$ 0.90	$ 3.07	$ 2.63
Shares used to compute Innoviva basic and diluted net income per share:
Shares used to compute basic net income per share	69,731	69,458	69,640	86,298
Shares used to compute diluted net income per share	95,830	81,699	95,072	98,536
Royalty revenue from a related party
Revenue:
Total revenue	$ 62,150	$ 97,862	$ 260,429	$ 284,186
Net product sales
Revenue:
Total revenue	5,107	0	5,107	0
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)	$ 3,680	$ 0	$ 3,680	$ 0